Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Long-Term Debt Repayments (2017 - 2021)

Historic Long-Term Debt Repayments for Ocular Therapeutix (OCUL) over the last 5 years, with Q2 2021 value amounting to $2.1 million.

  • Ocular Therapeutix's Long-Term Debt Repayments changed N/A to $2.1 million in Q2 2021 from the same period last year, while for Dec 2023 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $26.1 million for FY2023, which is N/A changed from last year.
  • Latest data reveals that Ocular Therapeutix reported Long-Term Debt Repayments of $2.1 million as of Q2 2021.
  • Over the past 5 years, Ocular Therapeutix's Long-Term Debt Repayments peaked at $2.1 million during Q2 2021, and registered a low of $1.0 million during Q1 2018.
  • Its 3-year average for Long-Term Debt Repayments is $1.6 million, with a median of $1.5 million in 2018.
  • Data for Ocular Therapeutix's Long-Term Debt Repayments shows a peak YoY increase of 2084.62% (in 2018) and a maximum YoY decrease of 2084.62% (in 2018) over the last 5 years.
  • Quarter analysis of 3 years shows Ocular Therapeutix's Long-Term Debt Repayments stood at $1.3 million in 2017, then increased by 18.69% to $1.5 million in 2018, then surged by 35.06% to $2.1 million in 2021.
  • Its last three reported values are $2.1 million in Q2 2021, $2.1 million for Q1 2021, and $1.5 million during Q4 2018.